Zymeworks Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $106.0 | $76.3 | $76.0 | $412.5 | $26.7 |
| Operating income | -$92.5 | -$137.1 | -$138.1 | $130.5 | -$215.6 |
| Net income | -$81.1 | -$122.7 | -$118.7 | $124.3 | -$211.8 |
| Cash Flow Statement | |||||
| Free cash flow | -$34.5 | -$112.0 | -$120.8 | $136.0 | -$204.9 |
| Share repurchases | $41.7 | $30.1 | $0.0 | $0.0 | — |
Shares outstanding 71.0M · Free float 54.5%
Annual filing data through FY ended December 31, 2025; float as of October 6, 2026.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
June 29, 2026
Economy Survey
Credit Lines and Coupon Math Anchor Week's Economy Commentary
June 29, 2026
Deals
Zymeworks to Buy Theravance Biopharma in $929 Million Cash Deal